Dosing & Uses

Type 2 Diabetes Mellitus

Once weekly SC injection pending FDA approval for type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control

Next:

Pharmacology

Mechanism of Action

Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist

GIP is an incretin hormone that induces insulin secretion in response to a meal (primarily by hyperosmolarity of glucose in the duodenum) to facilitate the metabolism of carbohydrates, fats, and proteins

GLP-1 receptor agonists increase insulin secretion in the presence of elevated blood glucose, suppress glucagon post prandial, delays gastric emptying to decrease postprandial glucose; also decreases glucagon secretion

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.